Guselkumab for the Treatment of Psoriasis

BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
Álvaro Machado, Tiago Torres

Abstract

Psoriasis is a common, chronic, immune-mediated, inflammatory skin disease with systemic involvement and significant impact on patients' quality of life. Several biologic treatments have been developed in recent decades, such as tumor necrosis factor (TNF)-α inhibitors, a non-selective interleukin (IL)-23 inhibitor (ustekinumab, which also inhibits IL-12), and-most recently-IL-17 inhibitors. Guselkumab is a novel biological therapy that selectively targets IL-23 and is the first-in-class selective IL-23 inhibitor approved to treat moderate-to-severe plaque psoriasis. These inhibitors are expected to have some advantages over the highly effective IL-17 inhibitors, as they do not worsen inflammatory bowel disease and are not involved in the development of candida infections. Additionally, selective inhibition of IL-23 may have additional benefits over ustekinumab as the IL-12-dependent cascades remain functional. These benefits include a decrease in IL-17A-producing T cells in the skin and the promotion of an anti-inflammatory effect through production of interferon-γ and IL-10. In terms of efficacy, guselkumab showed promising results in the treatment of psoriasis and psoriatic arthritis, although it did not show significant cli...Continue Reading

References

Aug 25, 1999·Journal of the American Academy of Dermatology·S R RappD M Reboussin
Aug 1, 1952·The Journal of Investigative Dermatology·M B SULZBERGER, V H WITTEN
Jan 21, 2006·The Journal of Immunology : Official Journal of the American Association of Immunologists·Gamze PiskinMarcel B M Teunissen
Sep 6, 2007·Annals of the New York Academy of Sciences·Hyun-Dong Chang, Andreas Radbruch
Apr 22, 2009·The Journal of Immunology : Official Journal of the American Association of Immunologists·Leslie van der FitsErik Lubberts
May 19, 2010·International Journal of Molecular Sciences·Therwa HamzaBingyun Li
Sep 28, 2012·The Journal of Investigative Dermatology·Rosa ParisiUNKNOWN Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team
Feb 27, 2014·Expert Opinion on Therapeutic Targets·Andrea ChiricozziJames G Krueger
Apr 1, 2014·The Journal of Allergy and Clinical Immunology·Howard SofenJames G Krueger
Jul 10, 2014·The New England Journal of Medicine·Richard G LangleyUNKNOWN FIXTURE Study Group
Aug 15, 2014·Drugs·Anthony Markham
Nov 22, 2014·Dermatologic Clinics·Jaehwan Kim, James G Krueger
Jun 1, 2015·Actas dermo-sifiliográficas·I Raposo, T Torres
Jul 15, 2015·The New England Journal of Medicine·Kenneth B GordonKristian Reich
Oct 1, 2015·The New England Journal of Medicine·Mark LebwohlAjay Nirula
Nov 14, 2015·Annual Review of Medicine·George E FragoulisIain B McInnes
Jun 15, 2016·The New England Journal of Medicine·Kenneth B GordonUNKNOWN UNCOVER-3 Study Group
Nov 29, 2016·Nature Communications·Paulina KuligBurkhard Becher
Apr 20, 2017·The New England Journal of Medicine·Kim A PappSteven J Padula
May 4, 2017·Current Cancer Drug Targets·Xinjie Lu
May 26, 2017·The British Journal of Dermatology·K ReichUNKNOWN IXORA-S investigators
Jun 3, 2017·Expert Opinion on Drug Safety·Bram VerstocktMarc Ferrante
Jun 28, 2017·Journal of the European Academy of Dermatology and Venereology : JEADV·G GirolomoniJ C Prinz
Aug 26, 2017·Gastroenterology Clinics of North America·Parakkal Deepak, William J Sandborn
Nov 15, 2017·The Annals of Pharmacotherapy·Seth T HowellSteven R Feldman
Jan 11, 2018·International Journal of Molecular Sciences·Andrea ChiricozziMarco Romanelli

❮ Previous
Next ❯

Citations

Jun 14, 2018·Expert Opinion on Drug Safety·M GalluzzoM Talamonti
Jul 13, 2019·International Journal of Molecular Sciences·Kübra Bunte, Thomas Beikler
Mar 15, 2020·The Journal of Immunology : Official Journal of the American Association of Immunologists·Xiaozhen HeQingguo Ruan
Mar 28, 2020·Inflammation Research : Official Journal of the European Histamine Research Society ... [et Al.]·Ahmad Ismail Khaled Abdo, Gee Jun Tye
May 7, 2019·Pharmaceutics·Esen SokulluMarc A Gauthier
May 28, 2019·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·Thomas Litman
Jan 3, 2020·Journal of Biomedical Science·Ruei-Min LuHan-Chung Wu
Oct 29, 2020·Molecular & Cellular Proteomics : MCP·Huan QiSheng-Ce Tao
Jan 26, 2021·Clinical, Cosmetic and Investigational Dermatology·Jeremy G LightSteven R Feldman
Feb 14, 2021·Molecular & Cellular Proteomics : MCP·Huan QiSheng-Ce Tao
Nov 12, 2021·Biotechnology and Bioengineering·Yeong Chae RyuByeong Hee Hwang

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT01018810
NCT03158285
NCT03162796
NCT03090100
NCT02343744
NCT02641730

Software Mentioned

NAVIGATE
reSURFACE
VOYAGE

Related Concepts

Related Feeds

Candida albicans

Candida albicans is an opportunistic, fungal pathogen of humans that frequently causes superficial infections of oral and vaginal mucosal surfaces of debilitated and susceptible individuals. Discover the latest research on Candida albicans here.

Candidiasis

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Candidiasis (ASM)

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.